<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Essential tremor: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Essential tremor: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Essential tremor: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andres Deik, MD, MSEd</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard I Hurtig, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Essential tremor (ET) is the most common cause of action tremor in adults  (<a class="graphic graphic_table graphicRef62078" href="/z/d/graphic/62078.html" rel="external">table 1</a>). It classically involves the hands and is brought out by arm movement and sustained antigravity postures, affecting common daily activities such as writing, drinking from a glass, and handling eating utensils.</p><p>ET is slowly progressive and can also involve the head, voice, and, uncommonly, the legs. Disability from the tremor can be significant, especially when the upper limbs are affected. A variety of symptomatic therapies are available.</p><p>In most cases, ET can be managed by primary care clinicians, beginning with exclusion of secondary causes and followed by initiation of therapy with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> or <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> if the tremor is causing disability. The decision to refer to a neurologist depends upon the clinician's confidence in the diagnosis, their comfort level with use of the drugs recommended for tremor suppression, and the patient's response to treatment.</p><p>This topic will review the treatment and prognosis of ET. Additional topics on tremor are available separately. (See  <a class="medical medical_review" href="/z/d/html/4895.html" rel="external">"Overview of tremor"</a> and  <a class="medical medical_review" href="/z/d/html/110665.html" rel="external">"Essential tremor: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4901.html" rel="external">"Surgical treatment of essential tremor"</a>.)</p><p class="headingAnchor" id="H757716661"><span class="h1">GOALS AND EXPECTATIONS</span><span class="headingEndMark"> — </span>Treatment of ET is symptomatic, and no disease-modifying therapies are available. The degree of tremor control provided by medications varies among patients and often depends on the dose of the agents used, tremor severity, and a patient's individual response to the chosen agent. Patients with mild tremor may experience complete tremor suppression with available therapies. However, the goal of therapy for most patients is to reduce tremor severity enough to prevent disability while minimizing medication side effects.</p><p>It is important to explain to patients that tremor will worsen over time, and that increased doses and second-line therapies will likely be required. Tremor progression is <strong>not</strong> indicative of an alternate diagnosis such as Parkinson disease as long as no additional signs or symptoms emerge  (<a class="graphic graphic_table graphicRef60694" data-inline-graphics="60694" href="/z/d/graphic/60694.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/110665.html" rel="external">"Essential tremor: Clinical features and diagnosis", section on 'Parkinson disease'</a>.)</p><p class="headingAnchor" id="H4073596416"><span class="h1">TREATMENT APPROACH</span></p><p class="headingAnchor" id="H1272897558"><span class="h2">Exacerbating and mitigating factors</span><span class="headingEndMark"> — </span>When possible, medications or other substances (eg, caffeine) that could be exacerbating tremor should be discontinued  (<a class="graphic graphic_table graphicRef119320" data-inline-graphics="119320" href="/z/d/graphic/119320.html" rel="external">table 3</a>); at times, doing this will suffice to control tremor, even if temporarily.</p><p>Alcohol is well-known to reduce tremor in many patients with ET and often has an effect in modest amounts (eg, a half to one glass of wine). Some patients find this effect useful in social situations. (See <a class="local">'Others'</a> below.)</p><p class="headingAnchor" id="H515891558"><span class="h2">Criteria for pharmacotherapy</span><span class="headingEndMark"> — </span>Drug treatment should be offered to patients with ET who have intermittent or persistent disability caused by tremor  (<a class="graphic graphic_algorithm graphicRef104216" href="/z/d/graphic/104216.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]. When possible, medications or other substances (eg, caffeine) that could be exacerbating tremor should be discontinued  (<a class="graphic graphic_table graphicRef119320" href="/z/d/graphic/119320.html" rel="external">table 3</a>); at times, doing this will suffice to control tremor, even if temporarily.</p><p>Individuals with mild ET and little or no tremor-related disability usually do not require treatment, although some patients are bothered by the cosmetic effect of even the smallest amount of shaking. Patients may not volunteer that they are bothered or embarrassed by the tremor, and it is important to assess both the physical and the psychosocial impact.</p><p class="headingAnchor" id="H587344136"><span class="h2">Patients with frequent/daily symptoms</span><span class="headingEndMark"> — </span>Patients with persistent functional or psychological disability (including embarrassment or anxiety) due to ET generally require a daily medication  (<a class="graphic graphic_algorithm graphicRef104216" data-inline-graphics="104216" href="/z/d/graphic/104216.html" rel="external">algorithm 1</a>). <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a>, a nonselective beta adrenergic blocker, and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, an antiseizure medication, are each considered first-line therapies for ET [<a href="#rid2">2,3</a>], and they have equivalent efficacy based on small comparative trials. The choice between these agents is based on side effect profiles, concomitant medications, and comorbidities. (See <a class="local">'Choice of agent'</a> below.)</p><p>For ET that does not respond adequately to monotherapy with either <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> or <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, the two drugs can be used together. Switching from one to the other is also a reasonable strategy if either agent is poorly tolerated. Several additional drugs or classes of drugs have more limited evidence of benefit for ET but can be tried as second-line agents, either alone or in combination with a first-line therapy. These include <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, benzodiazepines, and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. (See <a class="local">'Second-line therapies'</a> below.)</p><p>Additional options in patients with refractory ET include various adaptive devices, botulinum toxin (BoNT) injections, and surgical therapy. (See <a class="local">'Refractory tremor'</a> below.)</p><p class="headingAnchor" id="H1997141438"><span class="h2">Patients with situational exacerbations</span><span class="headingEndMark"> — </span>Some patients with ET develop exacerbations of tremor triggered by stressful social occasions or public performances. Intermittent drug treatment of ET in anticipation of these situations can be useful in such cases  (<a class="graphic graphic_algorithm graphicRef104216" href="/z/d/graphic/104216.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>].</p><p>Use of medication in this setting is individualized and may require a trial-and-error approach, as side effects are variable and may have adverse effects on performance. For most patients with mild ET who have situational exacerbations of tremor that cause concern, we suggest treatment as needed with low-dose <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>. (See <a class="local">'Propranolol'</a> below.)</p><p>Some experts report that <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> may also be effective when used intermittently for ET that is exacerbated by situational stress or anxiety, but its slow onset of action limits its utility in this setting. (See <a class="local">'Primidone'</a> below.)</p><p>Alternative options include judicious use of a low-dose short-acting benzodiazepine. In purely social settings, some patients find that a small amount of alcohol lessens tremor to an acceptable level. (See <a class="local">'Benzodiazepines'</a> below and <a class="local">'Others'</a> below.)</p><p class="headingAnchor" id="H4585256"><span class="h1">INITIAL PHARMACOTHERAPY</span></p><p class="headingAnchor" id="H2270034461"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>Of the available medications for ET, evidence of efficacy is most robust for <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> [<a href="#rid1">1-3</a>]. Although efficacy is similar and both are endorsed as clinically useful by expert guideline panels [<a href="#rid2">2,3</a>], we suggest propranolol as first-line therapy in most cases, based largely on side effect profile and drug interactions. Primidone is not commonly used as initial therapy except when there are contraindications to the use of propranolol.</p><p><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> each may reduce tremor amplitude by approximately 50 percent [<a href="#rid4">4</a>], according to evidence from three small clinical trials that compared the two drugs [<a href="#rid5">5-7</a>]. In the first of these, both propranolol and primidone significantly and equally reduced limb tremor compared with placebo [<a href="#rid5">5</a>]. Equivalent tremor reduction was found in the second trial after one week of propranolol treatment and two weeks of primidone treatment [<a href="#rid6">6</a>]. In vitro, these medications have been shown to influence the expression of genes related to calcium signaling, endosomal sorting, axon guidance, and neuronal morphology [<a href="#rid8">8</a>].</p><p>Neither drug is effective for all patients with ET, however. In an open-label study that examined <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> treatment for ET in 50 patients, propranolol had no therapeutic effect in 7 of 23 patients (30 percent) and primidone had no effect in 7 of 22 (32 percent) [<a href="#rid7">7</a>]. In addition, acute adverse reactions with primidone, especially drowsiness and ataxia, and chronic side effects of propranolol appear to be important limitations to the use of these drugs. However, some side effects of primidone can be self-limited (eg, "first-dose effect") and avoided by starting with a low dose and titrating as tolerated over several weeks.</p><p class="headingAnchor" id="H2988270922"><span class="h2">Administration and efficacy</span></p><p class="headingAnchor" id="H3"><span class="h3">Propranolol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> is the best-studied beta blocker for ET. Several other nonselective beta blockers appear to have similar benefits but are not as well studied. If a beta-1 selective agent is desired due to comorbidities such as asthma/bronchospasm, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> is usually chosen but may not be as effective as propranolol. (See <a class="local">'Other beta blockers'</a> below.)</p><p>Beta blockers are thought to impact tremor severity through action on adrenoreceptors in a deep compartment within muscle spindles [<a href="#rid9">9</a>]. In mice, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> has been shown to modulate the spiking activity of Purkinje cells and cerebellar nuclei neurons [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and formulation</strong> – Either immediate-release or extended-release (once daily) <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> can be used for ET, and they provide the same therapeutic response [<a href="#rid4">4</a>]. We prefer the extended-release formulation for daily use because it is more convenient [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">The usual starting dose of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for ET is 60 or 80 mg daily (divided two to four times per day for immediate-release). If a starting dose lower than 60 mg is desired due to comorbidities or advanced age, the immediate-release formulation can be used initially. The dose may be increased as needed at ≥1-week intervals up to a usual maximum of 360 mg daily [<a href="#rid3">3</a>]. The mean end-titration dose of propranolol for ET in nine trials was approximately 185 mg per day [<a href="#rid2">2,4</a>].</p><p></p><p class="bulletIndent1">Single doses of immediate-release <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> taken in anticipation of social situations that are likely to exacerbate tremor are useful in some patients. A single starting dose of 10 or 20 mg is suggested, which may be reasonably effective within an hour of taking the dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Side effects attributable to <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, including lightheadedness, fatigue, impotence, and bradycardia, occurred in 12 to 66 percent of patients in clinical trials [<a href="#rid4">4</a>]. As an example, one open-label study reported that such side effects led to discontinuation in 4 of 23 patients (17 percent) taking propranolol [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> is relatively contraindicated in the presence of heart block, unstable heart failure, asthma, and type 1 diabetes mellitus. (See  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers", section on 'Heart failure'</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p></p><p class="bulletIndent1">The American Academy of Neurology (AAN) guideline advises consultation with a cardiologist prior to starting <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in patients with cardiac disease [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A 2019 systematic review by the International Parkinson and Movement Disorder Society (MDS) identified 13 randomized trials in a total of 225 patients with ET comparing <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> with placebo (nine trials) or an active comparator (four trials) [<a href="#rid3">3</a>]. Daily doses of up to 360 mg were studied, and the median treatment duration was 3.5 weeks. Propranolol improved a range of outcome measures including tremor severity scores, task performance, activities of daily living, and objective accelerometer data. Overall, tremor magnitude was reduced by approximately 50 percent, and responder rates ranged from 50 to 70 percent [<a href="#rid3">3,12,13</a>]. Rates of functional improvement tended to be lower than responses measured by accelerometry.</p><p></p><p class="bulletIndent1">Evidence to support the efficacy of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for head and voice tremor is more limited and mixed [<a href="#rid2">2-4</a>]. The best-designed study, a randomized controlled trial involving 18 patients, found that propranolol reduced head tremor amplitude by approximately 50 percent, as measured by accelerometry [<a href="#rid14">14</a>]. However, propranolol was not effective for head tremor in two smaller studies [<a href="#rid15">15,16</a>]. It is important to remember that isolated head tremor suggests the presence of cervical dystonia, as opposed to essential tremor that is restricted to this area, and its management differs considerably. (See  <a class="medical medical_review" href="/z/d/html/132652.html" rel="external">"Cervical dystonia: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Primidone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">Primidone</a> is an antiseizure medication that is metabolized to <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> and phenylethylmalonamide. The mechanism of action for ET is unknown, and neither metabolite appears to influence tremor when used alone [<a href="#rid17">17,18</a>]. Primidone is used less commonly than <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> but has similar efficacy and is a reasonable alternative first-line agent for ET [<a href="#rid3">3</a>].</p><p><a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">Primidone</a> is a potent inducer of hepatic microsomal metabolizing enzymes. Thus, drug-drug interactions should be checked before primidone is added to existing medications. Specific interactions may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – We suggest starting <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> at 25 mg (one-half of the available 50 mg tablet) once daily before sleep. The dose should be titrated up carefully over several weeks as tolerated and according to therapeutic response. One suggested regimen is to titrate in 25 mg increments every three to seven days to a maximum of 250 mg at night, according to response and side effects. Sedation is usually the limiting factor with rapid titration or higher doses. Titration can be even slower for older adults.</p><p></p><p class="bulletIndent1">The medication should be withdrawn if there is no benefit using 250 mg each night. If there is a partial response at 250 mg nightly, the titration can continue up to 750 mg nightly as tolerated [<a href="#rid3">3,19,20</a>]. The mean end-titration dose of <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> for ET in three trials was approximately 480 mg/day [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Side effects from <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> are typically more severe at treatment initiation and may include sedation, drowsiness, fatigue, depression, nausea, vomiting, ataxia, malaise, dizziness, unsteadiness, confusion, vertigo, and an uncommon acute toxic reaction [<a href="#rid4">4</a>]. In an open-label study, transient acute side effects occurred in 8 of 22 patients (36 percent) assigned to primidone [<a href="#rid7">7</a>]. Use of a very low dose of primidone (7.5 mg) for initiation and titration did not improve tolerability in one study [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">Primidone</a> may be better tolerated in patients with epilepsy in whom hepatic enzymes have been induced by the previous administration of <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> or other antiseizure medications [<a href="#rid22">22,23</a>]. It is also possible that there are inherent characteristics of patients with ET that make them more prone to intolerance compared with epilepsy patients [<a href="#rid23">23</a>]. Nevertheless, stopping primidone because of adverse effects is not necessarily a contraindication to trying it again for ET; significant adverse effects may not recur if rechallenged with the medication, particularly if the rechallenge starting dose is low and the rate of increase is slow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Supportive evidence for <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> includes eight randomized trials in a total of 274 patients with ET comparing primidone with placebo (six trials) or an alternative formulation or dose of primidone (two trials) [<a href="#rid3">3</a>]. Doses studied ranged from 150 to 750 mg/day, and the average treatment duration was 10.1 weeks. Primidone improved tremor severity scores, task performance, and activities of daily living. A 12-month trial comparing two different doses of primidone (250 and 750 mg/day) found similar long-term efficacy and sustained benefit between the two doses. Primidone, up to 750 mg/day, is effective for the treatment of limb tremor associated with ET [<a href="#rid2">2,4</a>]. Similar to <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, tremor magnitude was reduced by approximately 50 percent, and clinical rating scales also improved by approximately 50 percent [<a href="#rid3">3,12,13</a>].</p><p></p><p class="bulletIndent1">Supportive evidence for vocal tremor is insufficient to draw firm conclusions [<a href="#rid3">3</a>]. A retrospective series reported that <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> was associated with improvement in vocal symptoms in 14 of 26 patients (54 percent) [<a href="#rid24">24</a>]. Of note, this study used categorical, subjective vocal outcomes and did not have a control group.</p><p></p><p class="headingAnchor" id="H1672673208"><span class="h3">Other beta blockers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> is the best-studied beta blocker for ET, but several other beta blockers, mainly nonselective agents, also have anti-tremor effects based on more limited evidence.</p><p>For nonselective agents like <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> and <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a>, in most instances there is no advantage to using these drugs for ET, since the evidence is stronger for <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> [<a href="#rid3">3</a>]. However, nadolol may still have a role, as it is a largely peripheral-acting beta blocker and may avoid adverse central effects that are sometimes induced by propranolol, such as depression [<a href="#rid4">4,12,25-27</a>].</p><p>Among beta-1 selective agents, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> is probably the best alternative to <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for patients with a relative contraindication to a nonselective beta blocker (eg, asthma or chronic obstructive lung disease). However, beta-1 selectivity is not absolute and may diminish at higher doses (eg, &gt;100 mg daily) (see  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>). <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">Metoprolol</a> is of uncertain benefit for ET.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atenolol</strong> – Two small randomized trials in patients with ET found that <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> improved symptoms [<a href="#rid28">28</a>] or accelerometer readings [<a href="#rid29">29</a>] compared with placebo. In the first study, which only included nine patients, atenolol was less effective than <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> [<a href="#rid28">28</a>]; the second found that both atenolol and propranolol were similarly effective compared with placebo [<a href="#rid29">29</a>]. The dose range of atenolol studied for ET is 50 to 150 mg daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metoprolol</strong><strong> </strong>– Data regarding its effectiveness are conflicting [<a href="#rid4">4</a>]. A randomized controlled trial found that a single dose of <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> 150 mg was effective for improving tremor [<a href="#rid30">30</a>]. However, a subsequent small, randomized, double-blind crossover study found that <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> improved outcomes compared with placebo, but metoprolol did not [<a href="#rid31">31</a>].</p><p></p><p>It appears that patients who do not respond to adequate doses of one beta blocker for ET are <strong>unlikely</strong> to respond to another [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3118939958"><span class="h2">Duration of benefit</span><span class="headingEndMark"> — </span>The symptomatic benefit of drugs used to treat ET declines over time, due either to disease progression or to the development of drug tolerance [<a href="#rid1">1,12</a>]. <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> remain effective for limb tremor reduction in most patients for at least one year, although increased doses of both drugs may be needed after 12 months of therapy [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H1700359700"><span class="h1">SECOND-LINE THERAPIES</span><span class="headingEndMark"> — </span>Medication options for ET that fails continuous treatment with first-line pharmacotherapy include using combination therapy with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, switching to the other first-line agent, and adding or switching to a second-line agent such as <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, a benzodiazepine, or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. Success rates are generally lower for second-line agents, and side effects may be dose limiting, especially for combination therapy or in older adults.</p><p>When tolerated, we favor <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> in combination before trying alternative second-line agents (see <a class="local">'Propranolol plus primidone'</a> below). For patients who fail first-line treatment due to side effects, we try the other first-line agent as monotherapy, when possible, before trying other second-line agents, which have less chance of benefit and/or more side effects.</p><p>For patients who fail or do not tolerate further pharmacologic treatment, options include use of adaptive devices, surgery with deep brain stimulation or thalamotomy to treat persistently disabling limb tremor, and botulinum toxin (BoNT) injections. (See <a class="local">'Refractory tremor'</a> below.)</p><p class="headingAnchor" id="H68392521"><span class="h2">Propranolol plus primidone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> plus <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> is our preferred second-line strategy for patients with inadequate benefit on first-line therapy, when possible, based on side effects and comorbidities. The combined use of these drugs is possibly more effective than either drug alone [<a href="#rid4">4</a>]. Supporting evidence includes two nonrandomized studies [<a href="#rid17">17,32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One study found that <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> monotherapy at the maximum effective dose (average 260 mg/day) reduced tremor amplitude by a mean of 35 percent; the addition of <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, 50 to 1000 mg/day, decreased tremor amplitude by a mean of 60 to 70 percent [<a href="#rid17">17</a>]. Acute reactions to primidone, including ataxia and confusion, occurred in 12 percent, and primidone titration was limited in others because of sedation and vertigo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study, the combined use of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> was more effective than either drug alone for the treatment of postural and kinetic tremor [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Topiramate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a>, when used at doses &gt;200 mg/day, is effective for reducing limb tremor associated with ET and improving functional disability, but its use is associated with a relatively high rate of adverse effects [<a href="#rid33">33</a>]. We avoid use in adults &gt;70 years of age due to risk of cognitive side effects.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and side effects</strong> – The initial dose of <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> is 25 mg once or twice a day, followed by weekly increases of 25 to 50 mg per day as tolerated up to a goal dose of at least 200 mg per day and a maximum total dose of 400 mg per day. The most common treatment-limiting adverse events in trials of topiramate for ET included paresthesias, reduced appetite, weight loss, somnolence, concentration/attention difficulty, and memory difficulty [<a href="#rid33">33</a>]. We avoid use of topiramate in patients over the age of 70 given the increased risk for cognitive side effects in this population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A 2019 systematic review identified four randomized controlled trials comparing <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> with placebo as monotherapy or add-on therapy in a total of 322 patients with ET [<a href="#rid3">3,33</a>]. The mean effective dose of topiramate in three trials ranged from 215 to 333 mg/day; one trial assessing a 50 to 100 mg dose range did not show a benefit.</p><p></p><p class="bulletIndent1">The largest controlled trial randomly assigned 223 patients with moderate to severe ET to 24 weeks of treatment with placebo or <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> (target dose 400 mg daily) as either monotherapy or adjunct therapy [<a href="#rid34">34</a>]. Topiramate treatment at a mean final dose of 292 mg daily resulted in a significantly greater improvement in a tremor rating scale, the primary outcome measure, than placebo. The degree of clinical improvement with topiramate was considered moderate, whereas that seen with placebo was mild. However, the rate of treatment-limiting adverse events was higher with topiramate than placebo (31.9 versus 9.5 percent, respectively).</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Benzodiazepines</span><span class="headingEndMark"> — </span>Benzodiazepines are widely used because of the usually mistaken belief that tremor is due to anxiety. Be that as it may, in patients in whom tremor is aggravated by anxiety, an anxiolytic may partially reduce tremor.</p><p>Caution is urged with the use of benzodiazepines for ET because of the potential for abuse and dependence, as well as the potential for drug discontinuation to cause withdrawal symptoms (including seizures) and tremor rebound. These problems make benzodiazepines a second-line choice for the chronic treatment of ET. The two benzodiazepines that have been studied for ET are <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> and <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">Alprazolam</a> may be useful for the treatment of limb tremor associated with ET in select patients [<a href="#rid2">2-4,12</a>], although high-quality data are lacking [<a href="#rid35">35</a>]. Two small clinical trials found that alprazolam, 0.125 to 3 mg/day, was associated with an improvement in clinical rating scales of 25 to 34 percent compared with placebo [<a href="#rid36">36,37</a>]. Side effects included mild sedation and fatigue. A tremor reduction of 69 and 76 percent (according to electromyography [EMG] data recorded at 40 and 80 minutes, respectively, after a dose of alprazolam) was documented in a study involving eight patients [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">Clonazepam</a> is occasionally used for the treatment of limb tremor associated with ET [<a href="#rid2">2,4,12</a>], although data are mixed. One clinical trial found that clonazepam 0.5 to 6 mg/day significantly reduced tremor [<a href="#rid39">39</a>], while another study found that clonazepam 0.4 to 4 mg/day was ineffective and resulted in a 40 percent study completion rate due to drowsiness [<a href="#rid40">40</a>].</p><p></p><p class="headingAnchor" id="H3098586974"><span class="h2">Gabapentin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> as monotherapy has antitremor effects in some patients with ET, but supporting data are very limited [<a href="#rid4">4,12,41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and side effects</strong> – If using <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> for ET, we suggest an initial dose of 100 to 300 mg three times daily, using the low end of the range for older adult patients. The dose can be titrated upwards as tolerated, typically by increasing the total daily dose by 300 mg every four to seven days. An effective range is not well established for ET, but 1200 mg daily was used in the only monotherapy trial [<a href="#rid42">42</a>]. Gabapentin may have fewer side effects than <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> but can cause sleepiness, dizziness, and gait unsteadiness, particularly in older adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – One small randomized controlled trial in six patients with new-onset ET and 10 patients previously treated with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> found that <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> 1200 mg/day reduced tremor compared with placebo [<a href="#rid42">42</a>]. Gabapentin as adjunct therapy has shown conflicting results for the treatment of ET [<a href="#rid4">4,43,44</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Others</span><span class="headingEndMark"> — </span>Antiseizure medications other than <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> have <strong>not </strong>shown consistent effects on ET, including <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> [<a href="#rid2">2,12,45-49</a>], <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> [<a href="#rid2">2,4</a>], <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> [<a href="#rid50">50-54</a>], and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid55">55-58</a>]. The noncompetitive glutamate receptor antagonist <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">perampanel</a> was superior to placebo in reducing tremor severity in one small crossover trial; however, it was also much more likely to cause imbalance/falls, dizziness, and irritability [<a href="#rid59">59</a>].</p><p>Alcohol has long been known to ameliorate ET [<a href="#rid60">60-62</a>]. Although the exact mechanism is not fully understood, a controlled study of 20 subjects with ET undergoing electroencephalography (EEG), EMG, and structural magnetic resonance imaging (MRI) observed a robust relationship between contralateral cerebellar coherence and change in tremor amplitude following alcohol intake [<a href="#rid63">63</a>]. A peripheral mechanism for tremor control is also possible [<a href="#rid61">61</a>]. Patients will often describe that small amounts of alcohol taken before meals or social events provide temporary tremor control, although the tremor tends to worsen when the effect of alcohol wears off. Regular (daily) use of alcohol to manage tremor is strongly discouraged.</p><p>Whether other alcohols exist that might have the same benefits on tremor without intoxicating effects is not yet clear. Oral 1-octanol showed promise in preliminary studies as a treatment for ET [<a href="#rid64">64-66</a>]. However, a small trial of octanoic acid (a metabolite of 1-octanol) only demonstrated benefit at 180 minutes in one study [<a href="#rid67">67</a>], approximately 110 minutes past the drug's expected plasma peak. The authors believe this delayed effect was the result of a second compartment (the central nervous system). No intoxication was observed in these studies. In a subsequent crossover study in 14 volunteers with ET, a single dose of octanoic acid (4 mg/kg) reduced tremor power in both the central and the peripheral component, as demonstrated by accelerometry data [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H3634510031"><span class="h1">REFRACTORY TREMOR</span></p><p class="headingAnchor" id="H511267954"><span class="h2">Adaptive devices</span><span class="headingEndMark"> — </span>Several different devices are being developed to noninvasively modulate and/or compensate for tremor severity [<a href="#rid69">69-71</a>]. All patients with ET may find benefit from adaptive devices, but patients with disabling tremor who either are not candidates for other treatment modalities or have suboptimal tremor control with them may be the best candidates for these technologies. Examples include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromodulation</strong> – In a randomized, sham-controlled pilot study involving 23 blinded subjects, noninvasive median and radial nerve stimulation resulted in an improvement in the Archimedes spiral drawing task [<a href="#rid72">72</a>]. Subsequent studies, including a larger sham-controlled trial in 77 patients and other open-label, lower quality studies, suggest that noninvasive neuromodulation therapy used repeatedly at home in 40-minute sessions is safe and improves patient-rated function and accelerometer-based tremor measurements during use of the device and for up to an hour afterwards [<a href="#rid73">73-75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biomechanical loading</strong> – Biomechanical loading refers to either the external application of force on a tremulous limb or the facilitation of antagonist muscle contraction within the limb to reduce tremor. At least two small research projects have explored different wearable robots to effectively suppress tremor [<a href="#rid76">76</a>]. One of the studies examined a robotic exoskeleton that applied forces to tremulous limbs, and the other was a neuroprosthesis capable of providing transcutaneous neurostimulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tremor cancellation devices</strong> – Commercially available tremor-canceling devices aim to facilitate activities such as eating in patients with hand tremor. In a double-blind study involving 15 study subjects, a noninvasive handheld device using Active Cancellation of Tremor (ACT) technology was shown to reduce tremor amplitude and severity for eating and transferring tasks [<a href="#rid77">77</a>]. The device used consists of a spoon or other utensil attachment, a motion-generating platform, a controller/sensor, and a power source.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local vibrational therapy</strong> – A small, uncontrolled study of a local hand-arm vibration device producing vibrations in the 8 to 18 Hz frequency range was found effective in some of the study subjects [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H973802428"><span class="h2">Botulinum toxin</span><span class="headingEndMark"> — </span>Botulinum toxin (BoNT) injections have shown variable benefits in trials for hand, voice, and head tremor and are associated with dose-dependent risk of weakness in the injected muscles [<a href="#rid2">2-4,12</a>]. However, they are endorsed by an International Parkinson and Movement Disorder Society (MDS) evidence-based review as possibly useful in clinical practice with specialized monitoring [<a href="#rid3">3</a>]. We discuss the option of BoNT therapy in patients who cannot tolerate or are uninterested in trying oral medications for tremor.</p><p class="headingAnchor" id="H1873959418"><span class="h3">Patient selection</span><span class="headingEndMark"> — </span>The best candidates for upper limb injections are patients whose tremor amplitude is mild enough to respond to low doses of BoNT type A (BoNT-A) or patients with severe and disabling upper limb tremor who would prefer hand weakness over tremor. Although reversible once the effects of BoNT wear off, hand weakness can be disabling while present, particularly when the dominant hand is affected. Only experienced limb injectors should administer this procedure.</p><p>For head and vocal tremor, there are also trade-offs between benefits and side effects. BoNT-A for voice tremor is associated with side effects that include breathiness, hoarseness, and swallowing difficulty [<a href="#rid2">2,4,79</a>], and common side effects with head tremor injections include dysphagia and neck weakness, stiffness, and/or pain. BoNT for vocal tremor is best administered by an otolaryngology specialist with expertise in treating ET.</p><p class="headingAnchor" id="H3146447184"><span class="h3">Administration and efficacy</span><span class="headingEndMark"> — </span>In the United States, three different types of BoNT-A are marketed: <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> (Dysport), <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">incobotulinumtoxinA</a> (Xeomin), and <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> (Botox); the efficacy of BoNT type B for ET has not been evaluated [<a href="#rid2">2,4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limb tremor</strong> – When used for limb tremor, BoNT-A is injected into forearm muscles (flexor carpi radialis and ulnaris, and extensor carpi radialis and ulnaris muscles). In the largest trial, 133 patients with ET were randomly assigned to low-dose BoNT-A (50 units), high-dose BoNT-A (100 units), or placebo [<a href="#rid80">80</a>]. Short-term improvement in clinical rating scales was reported, but there was no consistent improvement in motor tasks or functional disability. Dose-dependent hand weakness was observed for the low- and high-dose BoNT-A groups (30 and 70 percent, respectively). Additional side effects of BoNT-A included injection site pain, stiffness, cramping, hematoma, and paresthesias [<a href="#rid80">80</a>]. These side effects are likely to have interfered with blinded treatment and evaluation [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">In several studies, customized approaches to injection have improved the therapeutic ratio for hand tremor [<a href="#rid81">81</a>]. A blinded crossover trial in 33 patients with hand tremor investigated a customized approach to deliver 80 to 120 units of <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">incobotulinumtoxinA</a> into 8 to 14 hand and forearm muscles [<a href="#rid82">82</a>]. Compared with placebo, incobotulinumtoxinA injections led to improvements in tremor severity scores at four and eight weeks after injection. The incidence of hand weakness was very low (4 percent), in contrast to that observed in most previous studies (often &gt;50 percent). The use of electromyography (EMG) [<a href="#rid83">83</a>] or of kinematic technology also seems to have a role in improving the efficacy of BoNT-A injections for hand tremor and minimizing toxin-derived weakness [<a href="#rid84">84-86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Head tremor</strong> – When used for head tremor, BoNT-A is injected into sternocleidomastoid and splenius capitis muscles. In a randomized trial of 117 patients with essential or isolated head tremor, BoNT-A injections into each splenius capitus muscle improved patient-assessed head tremor severity compared with placebo injections, with expected waning of response by 12 weeks after each injection [<a href="#rid87">87</a>]. The proportion of patients with an improvement of at least two points on the clinical Global Impression of Change (CGI) scale at week 6 after the second injection was 31 percent in the BoNT-A group and 9 percent in the placebo group. Most secondary outcomes measuring function and objective tremor severity also favored BoNT-A. Adverse effects were more frequent with BoNT-A (47 versus 16 percent), most commonly headache or neck pain (34 percent), dysphagia (16 percent), posterior cervical weakness (15 percent), and cervical stiffness (10 percent). These results are consistent with earlier smaller studies [<a href="#rid88">88,89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voice tremor</strong> – For voice tremor, the injection target is one or both vocal folds. One study involving 15 patients found that self-reported benefit after BoNT-A occurred in 10 patients (67 percent) [<a href="#rid90">90</a>]. Side effects included voice weakness and breathiness lasting for one to two weeks after treatment in 12 patients (80 percent), and hoarseness and swallowing difficulty for four weeks in three patients (20 percent). Another study found that tremor severity was reduced after bilateral vocal cord injection in 3 of 10 patients (30 percent), and tremor was reduced after unilateral injection in two of nine patients (22 percent) [<a href="#rid91">91</a>]. Some patients undergoing injections may experience additive benefit from adjunctive oral medication [<a href="#rid92">92</a>].</p><p></p><p class="headingAnchor" id="H2116012882"><span class="h2">Surgical therapies</span><span class="headingEndMark"> — </span>Deep brain stimulation of the ventral intermediate nucleus of the thalamus, magnetic resonance imaging (MRI)-guided focused ultrasound, and stereotactic thalamotomy appear to be effective treatments for severely disabling, medication-resistant ET, as discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4901.html" rel="external">"Surgical treatment of essential tremor"</a>.)</p><p class="headingAnchor" id="H4584270"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Although prospective longitudinal data are limited, the usual course of ET is one of slow, gradual progression of tremor, which usually occurs over years [<a href="#rid93">93,94</a>]. Younger onset often correlates with a slower rate of progression, such that individuals with tremor since their teenage years may not require treatment until decades later.</p><p>Tremor often (but not always) starts in the hands and spreads to the neck and voice. Head tremor in patients with ET usually starts as an intermittent tremor in one direction (particularly "no-no") and eventually becomes more frequent and multiaxial [<a href="#rid95">95</a>]. ET may also remain stable in a minority of patients. However, a stable course should raise suspicion for an alternative diagnosis (eg, enhanced physiologic tremor or drug-induced tremor).</p><p>Although there are large variations in tremor amplitude and disability among patients with ET [<a href="#rid1">1</a>], it is a disabling condition for a substantial proportion of affected individuals [<a href="#rid96">96,97</a>]. Several reports suggest that functional disability in ET is associated with the amplitude of kinetic tremor in the upper limbs [<a href="#rid32">32,98,99</a>]. While prospective data are very limited, it has been suggested but not always agreed upon that ET may be associated with an increased risk for developing Parkinson disease [<a href="#rid100">100</a>]. Survival in ET does not differ from the general population [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H291799275"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118682.html" rel="external">"Society guideline links: Essential tremor"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16194.html" rel="external">"Patient education: Tremor (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/733.html" rel="external">"Patient education: Tremor (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3157703749"><span class="h1">PATIENT PERSPECTIVE TOPICS</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/141104.html" rel="external">"Patient perspective: Essential tremor with onset in childhood"</a> and  <a class="medical medical_review" href="/z/d/html/141156.html" rel="external">"Patient perspective: An artist with essential tremor"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Care setting</strong> – Essential tremor (ET) is the most common cause of action tremor in adults. In most cases, ET can be managed by primary care clinicians. Referral to a neurologist is appropriate when there is diagnostic uncertainty, poor response to standard pharmacotherapies, or disabling tremor. (See <a class="local">'Introduction'</a> above and <a class="local">'Goals and expectations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Criteria for treatment</strong> – Drug treatment should be offered to patients who have functional or psychological disability caused by tremor. Treatment of ET is symptomatic, and medications have variable benefits and side effects. (See <a class="local">'Criteria for pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial pharmacotherapy</strong> – Of the available medications, evidence for efficacy is most robust for <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>  (<a class="graphic graphic_algorithm graphicRef104216" href="/z/d/graphic/104216.html" rel="external">algorithm 1</a>). Efficacy is comparable between the two, and treatment selection and dosing are based on the nature of disability (frequent/daily or situational), side effects, drug interactions, and comorbidities.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frequent/daily symptoms</strong> – For most patients with frequent/daily functional or psychological disability due to ET, we suggest initial therapy with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> rather than <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Primidone is a reasonable alternative to propranolol when there is a desire to avoid beta blockers, and slow titration can help with tolerability. (See <a class="local">'Choice of agent'</a> above.)</p><p></p><p class="bulletIndent2">If a beta-1 selective beta blocker is preferred over <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> due to comorbidities, <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> is the best-studied alternative. (See <a class="local">'Other beta blockers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Situational exacerbations</strong> – For patients with mild ET who have situational exacerbations of tremor that cause disability, we suggest treatment as needed with low-dose, immediate-release <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other intermittent options include judicious use of a low-dose short-acting benzodiazepine or <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>. (See <a class="local">'Patients with situational exacerbations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line therapies</strong> – Success rates are generally lower for second-line agents, and side effects may be dose limiting, especially for combination therapy. When tolerated, we favor <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> in combination before trying alternative second-line agents such as <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, benzodiazepines, and/or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. (See <a class="local">'Second-line therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory tremor</strong> – For patients who fail pharmacologic treatment for ET, options include adaptive devices for limb tremor, surgery with deep brain stimulation or thalamotomy to treat persistently disabling limb tremor, and botulinum toxin (BoNT) injections to treat persistently disabling head or vocal cord tremor  (<a class="graphic graphic_algorithm graphicRef104216" href="/z/d/graphic/104216.html" rel="external">algorithm 1</a>). (See <a class="local">'Refractory tremor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The usual course of ET is one of slow, gradual progression. Younger onset often correlates with a slower rate of progression. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3519106892"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ludy Shih, MD, and Daniel Tarsy, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rajput AH, Rajput A. Medical treatment of essential tremor. J Cent Nerv Syst Dis 2014; 6:29.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011; 77:1752.</a></li><li><a class="nounderline abstract_t">Ferreira JJ, Mestre TA, Lyons KE, et al. MDS evidence-based review of treatments for essential tremor. Mov Disord 2019; 34:950.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005; 64:2008.</a></li><li><a class="nounderline abstract_t">Gorman WP, Cooper R, Pocock P, Campbell MJ. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry 1986; 49:64.</a></li><li><a class="nounderline abstract_t">Dietrichson P, Espen E. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels. Acta Neurol Scand 1987; 75:332.</a></li><li><a class="nounderline abstract_t">Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989; 39:1587.</a></li><li><a class="nounderline abstract_t">Castonguay CE, Liao C, Khayachi A, et al. Transcriptomic effects of propranolol and primidone converge on molecular pathways relevant to essential tremor. NPJ Genom Med 2022; 7:46.</a></li><li><a class="nounderline abstract_t">Abila B, Wilson JF, Marshall RW, Richens A. The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment. Br J Clin Pharmacol 1985; 20:369.</a></li><li><a class="nounderline abstract_t">Zhou J, Van der Heijden ME, Salazar Leon LE, et al. Propranolol Modulates Cerebellar Circuit Activity and Reduces Tremor. Cells 2022; 11.</a></li><li><a class="nounderline abstract_t">Koller WC. Long-acting propranolol in essential tremor. Neurology 1985; 35:108.</a></li><li><a class="nounderline abstract_t">Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol 2011; 10:148.</a></li><li><a class="nounderline abstract_t">Elias WJ, Shah BB. Tremor. JAMA 2014; 311:948.</a></li><li><a class="nounderline abstract_t">Koller WC. Propranolol therapy for essential tremor of the head. Neurology 1984; 34:1077.</a></li><li><a class="nounderline abstract_t">Sweet RD, Blumberg J, Lee JE, Mc Dowell FH. Propranolol treatment of essential tremor. Neurology 1974; 24:64.</a></li><li><a class="nounderline abstract_t">Calzetti S, Sasso E, Negrotti A, et al. Effect of propranolol in head tremor: quantitative study following single-dose and sustained drug administration. Clin Neuropharmacol 1992; 15:470.</a></li><li><a class="nounderline abstract_t">Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology 1986; 36:121.</a></li><li><a class="nounderline abstract_t">Calzetti S, Findley LJ, Pisani F, Richens A. Phenylethylmalonamide in essential tremor. A double-blind controlled study. J Neurol Neurosurg Psychiatry 1981; 44:932.</a></li><li><a class="nounderline abstract_t">Sasso E, Perucca E, Calzetti S. Double-blind comparison of primidone and phenobarbital in essential tremor. Neurology 1988; 38:808.</a></li><li><a class="nounderline abstract_t">Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry 1985; 48:911.</a></li><li><a class="nounderline abstract_t">O'Suilleabhain P, Dewey RB Jr. Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord 2002; 17:382.</a></li><li><a class="nounderline abstract_t">O'Brien MD, Upton AR, Toseland PA. Benign familial tremor treated with primidone. Br Med J (Clin Res Ed) 1981; 282:178.</a></li><li><a class="nounderline abstract_t">Lenka A, Louis ED. Primidone Intolerance in Essential tremor: Is it More than Just Age? Tremor Other Hyperkinet Mov (N Y) 2021; 11:57.</a></li><li><a class="nounderline abstract_t">Nida A, Alston J, Schweinfurth J. Primidone Therapy for Essential Vocal Tremor. JAMA Otolaryngol Head Neck Surg 2016; 142:117.</a></li><li><a class="nounderline abstract_t">Koller WC. Nadolol in essential tremor. Neurology 1983; 33:1076.</a></li><li><a class="nounderline abstract_t">Leigh PN, Jefferson D, Twomey A, Marsden CD. Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J Neurol Neurosurg Psychiatry 1983; 46:710.</a></li><li><a class="nounderline abstract_t">Teravainen H, Larsen A, Fogelholm R. Comparison between the effects of pindolol and propranolol on essential tremor. Neurology 1977; 27:439.</a></li><li><a class="nounderline abstract_t">Jefferson D, Jenner P, Marsden CD. beta-Adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry 1979; 42:904.</a></li><li><a class="nounderline abstract_t">Larsen TA, Teräväinen H, Calne DB. Atenolol vs. propranolol in essential tremor. A controlled, quantitative study. Acta Neurol Scand 1982; 66:547.</a></li><li><a class="nounderline abstract_t">Calzetti S, Findley LJ, Gresty MA, et al. Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry 1981; 44:814.</a></li><li><a class="nounderline abstract_t">Calzetti S, Findley LJ, Perucca E, Richens A. Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor. J Neurol Neurosurg Psychiatry 1982; 45:893.</a></li><li><a class="nounderline abstract_t">Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986; 36:1001.</a></li><li><a class="nounderline abstract_t">Bruno E, Nicoletti A, Quattrocchi G, et al. Topiramate for essential tremor. Cochrane Database Syst Rev 2017; 4:CD009683.</a></li><li><a class="nounderline abstract_t">Ondo WG, Jankovic J, Connor GS, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006; 66:672.</a></li><li><a class="nounderline abstract_t">Bruno E, Nicoletti A, Quattrocchi G, et al. Alprazolam for essential tremor. Cochrane Database Syst Rev 2015; :CD009681.</a></li><li><a class="nounderline abstract_t">Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology 1988; 38:241.</a></li><li><a class="nounderline abstract_t">Gunal DI, Afşar N, Bekiroglu N, Aktan S. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci 2000; 21:315.</a></li><li><a class="nounderline abstract_t">Ibáñez J, González de la Aleja J, Gallego JA, et al. Effects of alprazolam on cortical activity and tremors in patients with essential tremor. PLoS One 2014; 9:e93159.</a></li><li><a class="nounderline abstract_t">Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology 1987; 37:471.</a></li><li><a class="nounderline abstract_t">Thompson C, Lang A, Parkes JD, Marsden CD. A double-blind trial of clonazepam in benign essential tremor. Clin Neuropharmacol 1984; 7:83.</a></li><li><a class="nounderline abstract_t">Zappia M, Albanese A, Bruno E, et al. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol 2013; 260:714.</a></li><li><a class="nounderline abstract_t">Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999; 56:475.</a></li><li><a class="nounderline abstract_t">Ondo W, Hunter C, Vuong KD, et al. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord 2000; 15:678.</a></li><li><a class="nounderline abstract_t">Pahwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord 1998; 13:465.</a></li><li><a class="nounderline abstract_t">Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004; 19:1215.</a></li><li><a class="nounderline abstract_t">Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology 2005; 64:1078.</a></li><li><a class="nounderline abstract_t">Elble RJ, Lyons KE, Pahwa R. Levetiracetam is not effective for essential tremor. Clin Neuropharmacol 2007; 30:350.</a></li><li><a class="nounderline abstract_t">Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol 2004; 27:274.</a></li><li><a class="nounderline abstract_t">Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for the treatment of essential tremor. Mov Disord 2005; 20:640.</a></li><li><a class="nounderline abstract_t">Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord 2009; 24:437.</a></li><li><a class="nounderline abstract_t">Ondo WG. Zonisamide for essential tremor. Clin Neuropharmacol 2007; 30:345.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 2007; 22:279.</a></li><li><a class="nounderline abstract_t">Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 2005; 11:101.</a></li><li><a class="nounderline abstract_t">Bruno E, Nicoletti A, Filippini G, et al. Zonisamide for essential tremor. Cochrane Database Syst Rev 2017; 8:CD009684.</a></li><li><a class="nounderline abstract_t">Ferrara JM, Kenney C, Davidson AL, et al. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci 2009; 285:195.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Sullivan KL, Hinson V, et al. Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor. Mov Disord 2013; 28:249.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Ward CL, Hauser RA, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007; 22:1660.</a></li><li><a class="nounderline abstract_t">Bruno E, Nicoletti A, Quattrocchi G, et al. Pregabalin for essential tremor. Cochrane Database Syst Rev 2016; 10:CD009682.</a></li><li><a class="nounderline abstract_t">Handforth A, Tse W, Elble RJ. A Pilot Double-Blind Randomized Trial of Perampanel for Essential Tremor. Mov Disord Clin Pract 2020; 7:399.</a></li><li><a class="nounderline abstract_t">Growdon JH, Shahani BT, Young RR. The effect of alcohol on essential tremor. Neurology 1975; 25:259.</a></li><li><a class="nounderline abstract_t">Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology 1984; 34:221.</a></li><li><a class="nounderline abstract_t">Klebe S, Stolze H, Grensing K, et al. Influence of alcohol on gait in patients with essential tremor. Neurology 2005; 65:96.</a></li><li><a class="nounderline abstract_t">Pedrosa DJ, Nelles C, Brown P, et al. The differentiated networks related to essential tremor onset and its amplitude modulation after alcohol intake. Exp Neurol 2017; 297:50.</a></li><li><a class="nounderline abstract_t">Bushara KO, Goldstein SR, Grimes GJ Jr, et al. Pilot trial of 1-octanol in essential tremor. Neurology 2004; 62:122.</a></li><li><a class="nounderline abstract_t">Shill HA, Bushara KO, Mari Z, et al. Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. Neurology 2004; 62:2320.</a></li><li><a class="nounderline abstract_t">Voller B, Lines E, McCrossin G, et al. Dose-escalation study of octanoic acid in patients with essential tremor. J Clin Invest 2016; 126:1451.</a></li><li><a class="nounderline abstract_t">Haubenberger D, McCrossin G, Lungu C, et al. Octanoic acid in alcohol-responsive essential tremor: a randomized controlled study. Neurology 2013; 80:933.</a></li><li><a class="nounderline abstract_t">Cao H, Thompson-Westra J, Hallett M, Haubenberger D. The response of the central and peripheral tremor component to octanoic acid in patients with essential tremor. Clin Neurophysiol 2018; 129:1467.</a></li><li><a class="nounderline abstract_t">Castrillo-Fraile V, Peña EC, Gabriel Y Galán JMT, et al. Tremor Control Devices for Essential Tremor: A Systematic Literature Review. Tremor Other Hyperkinet Mov (N Y) 2019; 9.</a></li><li><a class="nounderline abstract_t">Lora-Millan JS, Delgado-Oleas G, Benito-León J, Rocon E. A Review on Wearable Technologies for Tremor Suppression. Front Neurol 2021; 12:700600.</a></li><li><a class="nounderline abstract_t">Nguyen HS, Luu TP. Tremor-Suppression Orthoses for the Upper Limb: Current Developments and Future Challenges. Front Hum Neurosci 2021; 15:622535.</a></li><li><a class="nounderline abstract_t">Lin PT, Ross EK, Chidester P, et al. Noninvasive neuromodulation in essential tremor demonstrates relief in a sham-controlled pilot trial. Mov Disord 2018; 33:1182.</a></li><li><a class="nounderline abstract_t">Isaacson SH, Peckham E, Tse W, et al. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor Other Hyperkinet Mov (N Y) 2020; 10:29.</a></li><li><a class="nounderline abstract_t">Pahwa R, Dhall R, Ostrem J, et al. An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. Neuromodulation 2019; 22:537.</a></li><li><a class="nounderline abstract_t">Dai D, Fernandes J, Kim H, Coetzer H. Comparative Effectiveness of Transcutaneous Afferent Patterned Stimulation Therapy for Essential Tremor: A Randomized Pragmatic Clinical Trial. Tremor Other Hyperkinet Mov (N Y) 2023; 13:38.</a></li><li><a class="nounderline abstract_t">Rocon E, Gallego JÁ, Belda-Lois JM, et al. Biomechanical loading as an alternative treatment for tremor: a review of two approaches. Tremor Other Hyperkinet Mov (N Y) 2012; 2.</a></li><li><a class="nounderline abstract_t">Pathak A, Redmond JA, Allen M, Chou KL. A noninvasive handheld assistive device to accommodate essential tremor: a pilot study. Mov Disord 2014; 29:838.</a></li><li><a class="nounderline abstract_t">Abramavičius S, Venslauskas M, Vaitkus A, et al. Local Vibrational Therapy for Essential Tremor Reduction: A Clinical Study. Medicina (Kaunas) 2020; 56.</a></li><li><a class="nounderline abstract_t">Khoury S, Randall DR. Treatment of Essential Vocal Tremor: A Scoping Review of Evidence-Based Therapeutic Modalities. J Voice 2022.</a></li><li><a class="nounderline abstract_t">Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56:1523.</a></li><li><a class="nounderline abstract_t">Mittal SO, Jog M, Lee J, Jabbari B. Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor - the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment. Tremor Other Hyperkinet Mov (N Y) 2020; 10:61.</a></li><li><a class="nounderline abstract_t">Mittal SO, Machado D, Richardson D, et al. Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. Parkinsonism Relat Disord 2018; 56:65.</a></li><li><a class="nounderline abstract_t">Liao YH, Hong CT, Huang TW. Botulinum Toxin for Essential Tremor and Hands Tremor in the Neurological Diseases: A Meta-Analysis of Randomized Controlled Trials. Toxins (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Samotus O, Rahimi F, Lee J, Jog M. Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future. PLoS One 2016; 11:e0153739.</a></li><li><a class="nounderline abstract_t">Zakin E, Simpson D. Botulinum Toxin in Management of Limb Tremor. Toxins (Basel) 2017; 9.</a></li><li class="breakAll">Jog M, Lee J, Althaus M, et al. Efficacy and safety of incobotulinumtoxinA (inco/A) for essential tremor using kinematics-guided clinical decision support: A randomized, double-blind, placebo-controlled trial. In: Proceedings of the Movement Disorder Society Meeting, Vancouver, BC, Canada, 4-8 June 2017.</li><li><a class="nounderline abstract_t">Marques A, Pereira B, Simonetta-Moreau M, et al. Trial of Botulinum Toxin for Isolated or Essential Head Tremor. N Engl J Med 2023; 389:1753.</a></li><li><a class="nounderline abstract_t">Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology 1995; 45:822.</a></li><li><a class="nounderline abstract_t">Wissel J, Masuhr F, Schelosky L, et al. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 1997; 12:722.</a></li><li><a class="nounderline abstract_t">Hertegård S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol 2000; 109:204.</a></li><li><a class="nounderline abstract_t">Warrick P, Dromey C, Irish JC, et al. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope 2000; 110:1366.</a></li><li><a class="nounderline abstract_t">Justicz N, Hapner ER, Josephs JS, et al. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. Laryngoscope 2016; 126:113.</a></li><li><a class="nounderline abstract_t">Louis ED, Agnew A, Gillman A, et al. Estimating annual rate of decline: prospective, longitudinal data on arm tremor severity in two groups of essential tremor cases. J Neurol Neurosurg Psychiatry 2011; 82:761.</a></li><li><a class="nounderline abstract_t">Louis ED, Michalec M, Gillman A. Shaky drawing: what is the rate of decline during prospective follow-up of essential tremor? BMJ Open 2014; 4:e004626.</a></li><li><a class="nounderline abstract_t">Robakis D, Louis ED. Head tremor in essential tremor: "Yes-yes", "no-no", or "round and round"? Parkinsonism Relat Disord 2016; 22:98.</a></li><li><a class="nounderline abstract_t">Louis ED, Okun MS. It is time to remove the 'benign' from the essential tremor label. Parkinsonism Relat Disord 2011; 17:516.</a></li><li><a class="nounderline abstract_t">Louis ED, Barnes L, Albert SM, et al. Correlates of functional disability in essential tremor. Mov Disord 2001; 16:914.</a></li><li><a class="nounderline abstract_t">Rajput A, Robinson CA, Rajput AH. Essential tremor course and disability: A clinicopathologic study of 20 cases. Neurology 2004; 62:932.</a></li><li><a class="nounderline abstract_t">Norman KE, D'Amboise SN, Pari G, Héroux ME. Tremor during movement correlates well with disability in people with essential tremor. Mov Disord 2011; 26:2088.</a></li><li><a class="nounderline abstract_t">Benito-León J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study Group. Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry 2009; 80:423.</a></li><li><a class="nounderline abstract_t">Rajput AH, Offord KP, Beard CM, Kurland LT. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry 1984; 47:466.</a></li></ol></div><div id="topicVersionRevision">Topic 4898 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24812533" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Medical treatment of essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22013182" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31046186" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : MDS evidence-based review of treatments for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972843" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3514797" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2887081" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2586774" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute and chronic effects of propranolol and primidone in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927430" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transcriptomic effects of propranolol and primidone converge on molecular pathways relevant to essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2866785" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36497147" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Propranolol Modulates Cerebellar Circuit Activity and Reduces Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965982" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-acting propranolol in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21256454" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24595779" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6379505" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Propranolol therapy for essential tremor of the head.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4855666" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Propranolol treatment of essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1477848" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of propranolol in head tremor: quantitative study following single-dose and sustained drug administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3941767" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy of primidone in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7031184" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Phenylethylmalonamide in essential tremor. A double-blind controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3283599" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Double-blind comparison of primidone and phenobarbital in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3900296" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primidone in essential tremor of the hands and head: a double blind controlled clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11921128" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomized trial comparing primidone initiation schedules for treating essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6779938" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Benign familial tremor treated with primidone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35070493" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primidone Intolerance in Essential tremor: Is it More than Just Age?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26660910" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primidone Therapy for Essential Vocal Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6348587" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nadolol in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6310053" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/558548" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison between the effects of pindolol and propranolol on essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/512665" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : beta-Adrenoreceptor antagonists in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7148397" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Atenolol vs. propranolol in essential tremor. A controlled, quantitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7031187" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Metoprolol and propranolol in essential tremor: a double-blind, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6815306" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2940473" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Disability in essential tremor: effect of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28409827" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Topiramate for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436648" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Topiramate in essential tremor: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26638213" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Alprazolam for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3340287" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of alprazolam for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11286044" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24667763" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of alprazolam on cortical activity and tremors in patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3822141" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Kinetic predominant essential tremor: successful treatment with clonazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6367975" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A double-blind trial of clonazepam in benign essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22886006" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199338" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928578" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613738" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Double-blind controlled trial of gabapentin in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15390011" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781835" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of levetiracetam on essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090460" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Levetiracetam is not effective for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613931" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : An open-label pilot study of levetiracetam for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15756652" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Levetiracetam for the treatment of essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117357" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Zonisamide for essential tremor: an evaluator-blinded study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090459" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Zonisamide for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17149715" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734668" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28836659" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Zonisamide for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19631949" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238907" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17580330" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27763691" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pregabalin for essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32373656" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Pilot Double-Blind Randomized Trial of Perampanel for Essential Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1167633" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The effect of alcohol on essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6538013" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effect of alcohol on tremors: comparison with propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009892" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Influence of alcohol on gait in patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28754506" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The differentiated networks related to essential tremor onset and its amplitude modulation after alcohol intake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14718713" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pilot trial of 1-octanol in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210907" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Open-label dose-escalation study of oral 1-octanol in patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26927672" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dose-escalation study of octanoic acid in patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408867" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Octanoic acid in alcohol-responsive essential tremor: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29678370" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The response of the central and peripheral tremor component to octanoic acid in patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31867136" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Tremor Control Devices for Essential Tremor: A Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34434161" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A Review on Wearable Technologies for Tremor Suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33994975" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Tremor-Suppression Orthoses for the Upper Limb: Current Developments and Future Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663525" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Noninvasive neuromodulation in essential tremor demonstrates relief in a sham-controlled pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32864188" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30701655" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37869579" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Comparative Effectiveness of Transcutaneous Afferent Patterned Stimulation Therapy for Essential Tremor: A Randomized Pragmatic Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439994" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Biomechanical loading as an alternative treatment for tremor: a review of two approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24375570" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A noninvasive handheld assistive device to accommodate essential tremor: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33096872" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Local Vibrational Therapy for Essential Tremor Reduction: A Clinical Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35022154" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Treatment of Essential Vocal Tremor: A Scoping Review of Evidence-Based Therapeutic Modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11402109" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33442486" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Novel Botulinum Toxin Injection Protocols for Parkinson Tremor and Essential Tremor - the Yale Technique and Sensor-Based Kinematics Procedure for Safe and Effective Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29929813" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35324700" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Botulinum Toxin for Essential Tremor and Hands Tremor in the Neurological Diseases: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27101283" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Functional Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined Biomechanical Patterns - A New Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29125566" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Botulinum Toxin in Management of Limb Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29125566" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Botulinum Toxin in Management of Limb Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37937777" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Trial of Botulinum Toxin for Isolated or Essential Head Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7723978" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Botulinum toxin treatment of essential head tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9380055" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685574" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Botulinum toxin injections for essential voice tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942143" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26198384" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436230" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Estimating annual rate of decline: prospective, longitudinal data on arm tremor severity in two groups of essential tremor cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24722199" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Shaky drawing: what is the rate of decline during prospective follow-up of essential tremor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563987" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Head tremor in essential tremor: "Yes-yes", "no-no", or "round and round"?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21486707" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : It is time to remove the 'benign' from the essential tremor label.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11746622" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Correlates of functional disability in essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037695" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Essential tremor course and disability: A clinicopathologic study of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21656852" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Tremor during movement correlates well with disability in people with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289477" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6736976" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Essential tremor in Rochester, Minnesota: a 45-year study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
